Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose
Your daily dose of the clinical news you may have missed.
The 2025 Winter Clinical Hawaii Dermatology Conference: Saturday Preview
The 2025 Winter Clinical Hawaii kicks off today with the first full day of educational sessions starting tomorrow, February 15 - here's what to look for.
Cannabis Use Disorder: FDA Grants Fast Track Status to Investigational Agent PP-01
The development comes at a time when cannabis use disorder has risen steadily in the United States.
5 Days in Hawaii: The Winter Clinical Hawaii Dermatology Conference
The Winter Clinical Hawaii Dermatology Conference will kick off on the Big Island on February 14th. Check out the agenda and the option to attend virtually.
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose
Dupilumab, Tezepelumab Gain Ground for Severe Asthma but Overall Biologic Adherence Rates Found Low: 2 Studies from 2025 AAAAI/WAO
AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.
Postnatal Antibiotics for Maternal Indications May Heighten Childhood Asthma Risk
AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.
AAAAI 2025: Omalizumab Shows Favorable Outcomes Versus Oral Immunotherapy in Multi‐Food Allergy Treatment
In a randomized clinical trial, omalizumab achieved a 36% treatment success rate for multi-food allergy compared with 19% for oral immunotherapy.
With the Flu Season in Overdrive, Hospitals are Overwhelmed
Some hospitals have EDs filled with patients and a number of states are reporting the 2024-2025 version of a COVID-19, flu, and RSV tripledemic.
Transdermal Peanut Patch Shows Increased Clinical Benefit Over 5-Year Study
AAAAI 2025. Treatment response rates with daily use of the VIASKIN peanut patch increased from 39% at baseline to 73.3% at 60 months in youth aged 4 to 11 years.
Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose
Overlap in Pathophysiology Suggests New Approaches to Acute Pain May Transfer to Relief from Chronic Pain: A Closer Look
Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.
Investigational Cell Therapy Cuts Insulin Dependency in Late-Stage Type 2 Diabetes
CELZ-201 reduced insulin dependency and stabilized HbA1c in 1-year follow-up data from a pilot study in T2D.
New Biomarkers Identified for Early Detection of Alzheimer Disease
Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.
Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-ILD Trial in Progressive Pulmonary Fibrosis
Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.
Heart Disease Remains Leading Cause of Death in US: Daily Dose
Suzetrigine (Journvax) Fits Neatly in a Multimodal Strategy to Manage Acute Pain, According to Edward Mariano, MD, MAS
Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.
Headaches and Suicide
The risk of a suicide attempt was 2 times greater among those with headache, across types including tension type headache, migraine, trigeminal autonomic cephalalgia, and posttraumatic headache.
FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis
Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.
FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C
The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.
